Table of Contents

2019-2024 Global Rheumatic Disorders Drug Market Report (Status and Outlook)

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Rheumatic Disorders Drug Market Size 2014-2024
  • 2.1.2 Rheumatic Disorders Drug Market Size CAGR by Region
• 2.2 Rheumatic Disorders Drug Segment by Type
  • 2.2.1 Acting on Tumor Necrosis Factor-Alpha
  • 2.2.2 Acting on Tumor Necrosis Factor-Alpha
  • 2.2.3 Acting on Protein Kinases
  • 2.2.4 Acting on Cell Surface Antigens
  • 2.2.5 Acting on Hormones and Hormone Receptors
  • 2.2.6 Others
• 2.3 Rheumatic Disorders Drug Market Size by Type
  • 2.3.1 Global Rheumatic Disorders Drug Market Size Market Share by Type (2014-2019)
  • 2.3.2 Global Rheumatic Disorders Drug Market Size Growth Rate by Type (2014-2019)
• 2.4 Rheumatic Disorders Drug Segment by Application
  • 2.4.1 Rheumatoid Arthritis
  • 2.4.2 Osteoarthritis
  • 2.4.3 Osteoporosis
  • 2.4.4 Systemic Lupus Erythematosus
  • 2.4.5 Psoriatic Arthritis
  • 2.4.6 Others
• 2.5 Rheumatic Disorders Drug Market Size by Application
  • 2.5.1 Global Rheumatic Disorders Drug Market Size Market Share by Application (2014-2019)
  • 2.5.2 Global Rheumatic Disorders Drug Market Size Growth Rate by Application (2014-2019)

3 Global Rheumatic Disorders Drug by Players

• 3.1 Global Rheumatic Disorders Drug Market Size Market Share by Players
  • 3.1.1 Global Rheumatic Disorders Drug Market Size by Players (2017-2019)
  • 3.1.2 Global Rheumatic Disorders Drug Market Size Market Share by Players (2017-2019)
• 3.2 Global Rheumatic Disorders Drug Key Players Head office and Products Offered
• 3.3 Market Concentration Rate Analysis
  • 3.3.1 Competition Landscape Analysis
  • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.4 New Products and Potential Entrants
• 3.5 Mergers & Acquisitions, Expansion

4 Rheumatic Disorders Drug by Regions

• 4.1 Rheumatic Disorders Drug Market Size by Regions
• 4.2 Americas Rheumatic Disorders Drug Market Size Growth
• 4.3 APAC Rheumatic Disorders Drug Market Size Growth
• 4.4 Europe Rheumatic Disorders Drug Market Size Growth
• 4.5 Middle East & Africa Rheumatic Disorders Drug Market Size Growth

5 Americas

• 5.1 Americas Rheumatic Disorders Drug Market Size by Countries
• 5.2 Americas Rheumatic Disorders Drug Market Size by Type
• 5.3 Americas Rheumatic Disorders Drug Market Size by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Rheumatic Disorders Drug Market Size by Countries
• 6.2 APAC Rheumatic Disorders Drug Market Size by Type
• 6.3 APAC Rheumatic Disorders Drug Market Size by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Rheumatic Disorders Drug by Countries
• 7.2 Europe Rheumatic Disorders Drug Market Size by Type
• 7.3 Europe Rheumatic Disorders Drug Market Size by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Rheumatic Disorders Drug by Countries
• 8.2 Middle East & Africa Rheumatic Disorders Drug Market Size by Type
• 8.3 Middle East & Africa Rheumatic Disorders Drug Market Size by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Global Rheumatic Disorders Drug Market Forecast

• 10.1 Global Rheumatic Disorders Drug Market Size Forecast (2019-2024)
• 10.2 Global Rheumatic Disorders Drug Forecast by Regions
  • 10.2.1 Global Rheumatic Disorders Drug Forecast by Regions (2019-2024)
  • 10.2.2 Americas Market Forecast
  • 10.2.3 APAC Market Forecast
  • 10.2.4 Europe Market Forecast
  • 10.2.5 Middle East & Africa Market Forecast
• 10.3 Americas Forecast by Countries
  • 10.3.1 United States Market Forecast
  • 10.3.2 Canada Market Forecast
  • 10.3.3 Mexico Market Forecast
  • 10.3.4 Brazil Market Forecast
• 10.4 APAC Forecast by Countries
  • 10.4.1 China Market Forecast
  • 10.4.2 Japan Market Forecast
  • 10.4.3 Korea Market Forecast
  • 10.4.4 Southeast Asia Market Forecast
  • 10.4.5 India Market Forecast
  • 10.4.6 Australia Market Forecast
• 10.5 Europe Forecast by Countries
  • 10.5.1 Germany Market Forecast
  • 10.5.2 France Market Forecast
  • 10.5.3 UK Market Forecast
  • 10.5.4 Italy Market Forecast
  • 10.5.5 Russia Market Forecast
  • 10.5.6 Spain Market Forecast
• 10.6 Middle East & Africa Forecast by Countries
  • 10.6.1 Egypt Market Forecast
  • 10.6.2 South Africa Market Forecast
  • 10.6.3 Israel Market Forecast
  • 10.6.4 Turkey Market Forecast
  • 10.6.5 GCC Countries Market Forecast
• 10.7 Global Rheumatic Disorders Drug Forecast by Type
• 10.8 Global Rheumatic Disorders Drug Forecast by Application

11 Key Players Analysis

• 11.1 AbbVie
  • 11.1.1 Company Details
  • 11.1.2 Rheumatic Disorders Drug Product Offered
  • 11.1.3 AbbVie Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.1.4 Main Business Overview
  • 11.1.5 AbbVie News
• 11.2 Amgen
  • 11.2.1 Company Details
  • 11.2.2 Rheumatic Disorders Drug Product Offered
  • 11.2.3 Amgen Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.2.4 Main Business Overview
  • 11.2.5 Amgen News
• 11.3 Johnson & Johnson
  • 11.3.1 Company Details
  • 11.3.2 Rheumatic Disorders Drug Product Offered
  • 11.3.3 Johnson & Johnson Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.3.4 Main Business Overview
  • 11.3.5 Johnson & Johnson News
• 11.4 Novartis
  • 11.4.1 Company Details
  • 11.4.2 Rheumatic Disorders Drug Product Offered
  • 11.4.3 Novartis Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.4.4 Main Business Overview
  • 11.4.5 Novartis News
• 11.5 Pfizer
  • 11.5.1 Company Details
  • 11.5.2 Rheumatic Disorders Drug Product Offered
  • 11.5.3 Pfizer Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.5.4 Main Business Overview
  • 11.5.5 Pfizer News
• 11.6 Roche
  • 11.6.1 Company Details
  • 11.6.2 Rheumatic Disorders Drug Product Offered
  • 11.6.3 Roche Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.6.4 Main Business Overview
  • 11.6.5 Roche News
• 11.7 Eli Lilly
  • 11.7.1 Company Details
  • 11.7.2 Rheumatic Disorders Drug Product Offered
  • 11.7.3 Eli Lilly Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.7.4 Main Business Overview
  • 11.7.5 Eli Lilly News
• 11.8 Bristol-Myers Squibb
  • 11.8.1 Company Details
  • 11.8.2 Rheumatic Disorders Drug Product Offered
  • 11.8.3 Bristol-Myers Squibb Rheumatic Disorders Drug Revenue, Gross Margin and Market Share (2017-2019)
  • 11.8.4 Main Business Overview
  • 11.8.5 Bristol-Myers Squibb News

12 Research Findings and Conclusion

Treatment of drugs for regulating rheumatic diseases
Rheumatic diseases are a series of diseases characterized by chronic pain. Some of the most common diseases are osteoarthritis (OA) and rheumatoid arthritis (RA), and most rheumatic diseases use basically universal pain control drugs. Treatment is ongoing and there are no treatments for any of the key indications, so there is a need to develop better disease modulating drugs.

According to this study, over the next five years the Rheumatic Disorders Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Rheumatic Disorders Drug business, shared in Chapter 3.

This report presents a comprehensive overview, market shares and growth opportunities of Rheumatic Disorders Drug market by product type, application, key companies and key regions.

This study considers the Rheumatic Disorders Drug value generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019 in Section 2.3; and forecast to 2024 in section 10.7.
Acting on Tumor Necrosis Factor-Alpha
Acting on Interleukins and Interleukin Receptors
Acting on Protein Kinases
Acting on Cell Surface Antigens
Acting on Hormones and Hormone Receptors
Others
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 10.8.
Rheumatoid Arthritis
Osteoarthritis
Osteoporosis
Systemic Lupus Erythematosus
Psoriatic Arthritis
Others

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
AbbVie
Amgen
Johnson & Johnson
Novartis
Pfizer
Roche
Eli Lilly
Bristol-Myers Squibb

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key players and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Rheumatic Disorders Drug market size by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Rheumatic Disorders Drug market by identifying its various subsegments.
Focuses on the key global Rheumatic Disorders Drug players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Rheumatic Disorders Drug with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the size of Rheumatic Disorders Drug submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.